Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Down 3.8%

Calliditas Therapeutics AB (publ) (NASDAQ:CALT)’s stock price fell 3.8% during mid-day trading on Tuesday . The stock traded as low as $21.00 and last traded at $21.00. 859 shares changed hands during trading, a decline of 90% from the average session volume of 8,498 shares. The stock had previously closed at $21.84.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research note on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Stock Down 2.2 %

The firm’s 50 day moving average is $21.78 and its two-hundred day moving average is $20.24. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89. The stock has a market cap of $625.89 million, a price-to-earnings ratio of -12.81 and a beta of 1.51.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last released its earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. Calliditas Therapeutics AB (publ) had a negative net margin of 38.72% and a negative return on equity of 104.47%. The company had revenue of $42.45 million during the quarter, compared to the consensus estimate of $36.24 million. During the same quarter in the prior year, the firm earned ($0.01) EPS. On average, sell-side analysts predict that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Institutional Trading of Calliditas Therapeutics AB (publ)

Several large investors have recently made changes to their positions in CALT. Deutsche Bank AG lifted its position in Calliditas Therapeutics AB (publ) by 26.5% during the 1st quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock worth $2,170,000 after acquiring an additional 18,978 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Calliditas Therapeutics AB (publ) during the 1st quarter worth about $221,000. Tower Research Capital LLC TRC boosted its stake in Calliditas Therapeutics AB (publ) by 1,270.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock valued at $51,000 after purchasing an additional 3,112 shares during the period. Finally, Optiver Holding B.V. acquired a new stake in Calliditas Therapeutics AB (publ) in the 4th quarter valued at approximately $25,000. Institutional investors own 2.83% of the company’s stock.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.